Key result
Azithromycin is linked to abnormal cardiac electrophysiology and increased risk of QT prolongation and arrhythmias.
Why the study?
Does azithromycin use increase the risk of QT-prolongation and cardiac arrhythmias?
Does azithromycin use increase the risk of QT-prolongation and cardiac arrhythmias?
Clinicians must be aware of the risk of QT-prolongation and arrhythmias when prescribing azithromycin, particularly considering concomitant medications and patient comorbidities.
Azithromycin warrants ECG vigilance in patients with QT risk factors; leaves open precise arrhythmia incidence from higher-level evidence.
Azithromycin is a commonly prescribed macrolide antibiotic for the management of community-acquired pneumonia in the outpatient setting. Recent data have led to a growing concern of abnormal changes in cardiac electrophysiology and arrhythmias associated with its use. As azithromycin continues to be prescribed, clinicians should be aware of the new safety data and how it may affect concomitant medications or comorbid conditions in a patient. This article utilizes a case-based approach to assess azithromycin use and the risk of QT-prolongation and cardiac arrhythmias.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2014) conducted a review in Community-acquired pneumonia. Azithromycin was evaluated on QT-prolongation and cardiac arrhythmias. Azithromycin use is associated with abnormal changes in cardiac electrophysiology and an increased risk of QT-prolongation and cardiac arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: